METHUSELAH ARCHIVE INGREDIENTS / NMN (NICOTINAMIDE MONONUCLEOTIDE)

NMN (nicotinamide mononucleotide)

synthetic
provenance:synthetic
first introduced:2013
regulatory status:supplement
context:NMN is a naturally occurring precursor of NAD+ (nicotinamide adenine dinucleotide), a molecule required for hundreds of cellular enzymatic reactions and known to decline with age. It entered longevity science prominently in December 2013, when a Harvard Medical School team including David Sinclair reported in Cell that NMN supplementation restored some markers of youthful muscle function in old mice. Sinclair's laboratory published further mouse work in 2018 (Cell) reporting that NMN restored blood-vessel density and exercise capacity in aged mice.
MECHANISM CLAIMED
Raises cellular NAD+ levels, which in turn is proposed to restore activity of SIRT1 and other sirtuins, repairing age-related declines in mitochondrial function, DNA repair, and tissue vitality.
MECHANISM ACTUAL
Human trials confirm NMN supplementation raises blood NAD+-related markers, and some small studies report modest improvements in specific metabolic parameters, but a May 2026 review by two Kingston University biologists in The Conversation concludes recent analyses have 'not found convincing evidence that NMN or NR preserve muscle mass or function in older adults' and that on outcomes closer to everyday aging — strength, cognition, frailty, biological age — 'the picture is much less clear'; no trial has shown NMN slows human aging or extends lifespan. NMN's regulatory status has also been contested: the FDA determined in a 4 November 2022 letter that NMN was excluded from the legal definition of a dietary supplement because Metro International Biotech (a company David Sinclair co-founded) had an active Investigational New Drug application for its proprietary NMN formulation MIB-626 (SupplySide Supplement Journal, 28 August 2024); trade press reported the FDA reversed that determination in a September 2025 letter, again permitting NMN as a supplement (AboutNAD, 8 October 2025).
INTERVENTIONS USING IT
EXTERNAL REFERENCES
NOTES

NMN is the second act of this case: after resveratrol’s mechanistic story collapsed and Sirtris was shut down, Sinclair’s public longevity advocacy shifted to NAD+ boosters, of which NMN is the most closely associated with his own lab and personal daily regimen. The commercial history repeats several structural features of the resveratrol story: mouse data described as dramatic, an ingredient Sinclair personally promotes and takes, a Sinclair-linked company (MetroBiotech) with a direct financial stake in the ingredient’s regulatory classification, and — as of a 2026 peer-reviewed-adjacent review — human evidence that has not caught up to the marketing.